Treace to Report Second Quarter 2022 Financial Results on August 9, 2022

Rhea-AI Summary

Treace Medical Concepts, Inc. (NasdaqGS: TMCI) will release its Q2 2022 financial results on August 9, 2022, post-market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Treace focuses on advanced surgical treatments for bunions, a condition affecting approximately 65 million Americans, with 1.1 million being surgical candidates annually. The company has developed the patented Lapiplasty® 3D Bunion Correction™ system and recently introduced the Adductoplasty™ Midfoot Correction System to further enhance treatment options.

Positive

• Innovative surgical solutions like Lapiplasty® and Adductoplasty™ for bunion treatment.
• Large target market with 65 million Americans affected by bunions.
• 1.1 million annual surgical candidates indicating strong market potential.

Negative

• None.

PONTE VEDRA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 9, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

FAQ

When will Treace Medical Concepts release its Q2 2022 financial results?

Treace Medical Concepts will release its Q2 2022 financial results on August 9, 2022.

What is the purpose of the conference call on August 9, 2022?

The conference call will discuss Treace Medical Concepts' financial results for Q2 2022.

What is Treace Medical Concepts' focus area?

Treace Medical Concepts focuses on surgical treatments for bunion deformities and related midfoot correction.

How many Americans are affected by bunions?

Approximately 65 million Americans are affected by bunions.

What systems does Treace Medical Concepts offer for bunion treatment?

Treace offers the Lapiplasty® 3D Bunion Correction™ system and the Adductoplasty™ Midfoot Correction System.